Acute respiratory distress syndrome (ARDS) is a devastating, proinflammatory disorder
resulting from sepsis or severe pneumonia such as SARS-Cov-2. A pathognomonic feature of
ARDS is severe tissue injury secondary to a profound release of host cell cytokines. Activation
of tumor necrosis factor receptor associated factor (TRAF) and the inflammasome proteins are
crucial to inflammation as these proteins link cell surface signals to cytokine release. The
mechanistic platform of this proposal resides on our discovery of a relatively new protein,
Fbxo3, a ubiquitin E3 ligase subunit, that potently stimulates cytokine secretion from human
inflammatory cells by activating TRAFs and inflammasomes. We previously designed and
advanced an Fbxo3 inhibitor, BC-1261, to an open IND, however, development was halted as
seizures were observed preclinically, limiting dosing in the clinic and thereby minimizing the
likelihood of achieving efficacious exposures in humans. Recognizing the opportunity to build
upon the achievements of BC-1261, the research strategy outlined in this application is
designed with specific milestones to address the critical shortcomings of BC-1261. Here, we
propose medicinal chemistry and lead optimization to develop and deliver a potent small-
molecule Fbxo3-targeted development candidate with an improved therapeutic index of
efficacy to seizure potential (Aim 1). We will also execute pharmacodynamics and
pharmacokinetic (PK) studies of lead compounds to nominate a suitable development
candidate for IND-enabling studies (Aim 2). Additionally, the candidate will demonstrate dose-
dependent oral activity in three translatable ARDS experimental models including a SARS-
Cov-2 hamster model with PK properties that support a hospital-based, critical-care therapeutic
to inhibit the dysfunctional immune response in acute lung injury patients. Successful
completion of this program will bring forth a transformative, first-in-class oral E3 ligase
pharmacotherapeutic for critical illness.